Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats

Neuropsychopharmacology

Volumn 31, Issue 9, 2006, Pages 1938-1945

  Hartfield, Abegale W ^a   Moore, Nicholas A ^b   Clifton, Peter G ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Food intake; Hyperphagia; Locomotor activity; Olanzapine; Rat; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; COCAINE; HALOPERIDOL; INTRALIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; COCAINE; DIBENZOTHIAZEPINES; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FAT EMULSIONS, INTRAVENOUS; FEMALE; HYPERKINESIS; MALE; MOTOR ACTIVITY; PIPERAZINES; RATS; RISPERIDONE; THIAZOLES;

EID: 33747361348     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300949     Document Type: Article

References (48)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
2. Arnt J (1995). Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283: 55-62.
3. Arvanitis LA, Miller BG (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42: 233-246.
4. Baptista T (2002). Mechanisms of weight gain induced by antipsychotic drugs. J Clin Psychiatry 63: 245-246.
5. Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu S, Walker D, Joober R et al (2002). Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 957: 144-151.
6. Baptista T, Parada M, Hernandez L (1987). Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27: 399-405.
7. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001). Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62: 231-238.
8. Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124: 159-167.
9. Borison RL, Arvanitis LA, Miller BG (1996). ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 16: 158-169.
10. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C et al (1998). Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3: 76-80.
11. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
12. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J et al (1992). Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85: 295-305.
13. Clifton PG (1994). The neuropharmacology of meal patterning. In: Cooper SJ, Hendrie CA (eds). Ethology and Psychopharmacology. Wiley: Chichester.
14. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491-505.
15. Dwyer DS, Donohoe D (2003). Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75: 255-260.
16. Emsley RA (1999). Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 25: 721-729.
17. Esel E, Basturk M, Saffet Gonul A, Kula M, Tayfun Turan M, Yabanoglu I et al (2001). Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology 26: 641-647.
18. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al (2002). Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159: 1055-1057.
19. Guyon A, Assouly-Besse F, Biala G, Puech AJ, Thiebot MH (1993). Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacology 110: 460-466.
20. Hartfield AW, Moore NA, Clifton PG (2003a). Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 167: 115-122.
21. Hartfield AW, Moore NA, Clifton PG (2003b). Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav 76: 251-258.
22. Hemphill RE, Pascoe FD, Zabow T (1975). An investigation of clozapine in the treatment of acute and chronic schizophrenia and gross behaviour disorders. S Afr Med J 49: 2121-2125.
23. Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002). Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71: 691-700.
24. Kaur G, Kulkarni SK (2002). Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 26: 277-285.
25. Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP et al (1998). Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140: 173-184.
26. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V et al (1997). SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609-620.
27. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M et al (1999). Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156: 312-314.
28. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
29. Lee MD, Clifton PG (1992). Free-feeding and free-drinking patterns of male rats following treatment with opiate kappa agonists. Physiol Behav 52: 1179-1185.
30. Markianos M, Hatzimanolis J, Lykouras L (1999). Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 9: 533-536.
31. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K et al (2003). Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 48: 689-694.
32. Moore NA (1999). Behavioural pharmacology of the new generation of antipsychotic agents. Br J Psychiatry 174(Suppl 38): 5-11.
33. Morien A, Cassone VM, Wellman PJ (1999). Diurnal changes in paraventricular hypothalamic alpha1 and alpha2-adrenoceptors and food intake in rats. Pharmacol Biochem Behav 63: 33-38.
34. Morimoto T, Yamamoto Y, Yamatodani A (2001). Brain histamine and feeding behavior. Behav Brain Res 124: 145-150.
35. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K et al (1984). Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459-474.
36. Parada MA, Hernandez L, Paez X, Baptista T, Puig de Parada M et al (1989). Mechanism of the body weight increase induced by systemic sulpiride. Pharmacol Biochem Behav 33: 45-50.
37. Peuskens J (1995). Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, doubleblind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166: 712-726; discussion 727-733.
38. Sanders NM, Ritter S (2000). Repeated 2-deoxy-D-glucose-induced glucoprivation attenuates Fos expression and glucoregulatory responses during subsequent glucoprivation. Diabetes 49: 1865-1874.
39. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
40. Simansky KJ, Vaidya AH (1990). Behavioral mechanisms for the anorectic action of the serotonin (5-HT) uptake inhibitor sertraline in rats: comparison with directly acting 5-HT agonists. Brain Res Bull 25: 953-960.
41. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG (1997). Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54: 549-557.
42. Taylor DM, McAskill R (2000). Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101: 416-432.
43. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF et al (1995). Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374: 542-546.
44. Thornton-Jones Z, Neill JC, Reynolds GP (2002). The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol 16: 35-37.
45. Tollefson GD, Beasley Jr CM, Tran PV, Street JS, Krueger JA, Tamura RN et al (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-465.
46. Turrone P, Kapur S, Seeman MV, Flint AJ (2002). Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159: 133-135.
47. Wellman PJ (2000). Norepinephrine and the control of food intake. Nutrition 16: 837-842.
48. Wetterling T (2001). Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety 24: 59-73.